Form 8-K GILEAD SCIENCES INC For: Jul 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Gilead Sciences (GILD) PT Raised to $90 at RBC Capital
July 26, 2018 7:58 AM EDTRBC Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $87.00) while maintaining an Outperform rating following results.
Analyst Brian Abraham commented, "With strong HIV sales and HCV stabilizing, GILD seems to be tracking towards steadier earnings base upon which... More
